In this case, Amgen Inc., a California-based pharmaceutical company, faced multiple lawsuits for accusations of perpetrating Medicare and Medicaid kickback schemes and two whistleblowing lawsuits. According to Staton, Amgen was eager to promote the sale of its new drug Aranesp, which it allegedly “pushed for off-label marketing to cancer patients”. The lawsuits alleged Amgen enticed long-term pharmacy providers to switch its Medicare and Medicaid patient prescriptions to Aranesp in exchange for kickbacks in the form of rebates and luxury vacations. The whistleblower suits, on the other hand, accused Amgen of wrongful termination because an employee identified the company’s failure to report all the complaints and problems with its new drug……………………….